This article has multiple issues. Please help or discuss these issues on the improve it . talk page ( Learn how and when to remove these template messages)
This article needs attention from an expert in Pharmacology. The specific problem is: tersely written and references unclear. (April 2013)
This article provides insufficient context for those unfamiliar with the subject. (April 2013)
DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and now licensed to the larger pharmaceutical company Merck & Co., which is currently in clinical trials. It is a so-called  triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).  It is the  racemic mixture of amitifadine (DOV-21,947) and its (–)- enantiomer, DOV-102,677. Its IC values for 50 SERT, NET, and DAT are K i 14 nM, 20 nM, and 78 nM, respectively. All DOV compounds are being developed in collaboration with Merck. 
Doses of up to 100 mg per day are well tolerated with only nausea, and GI disturbances reported as side effects.
This compound does not cause notable shifts in LMA, and is not psychostimulant.
The effects are not long-lasting.
More recently (see attachment), it appears that the DOV compound may also be useful at increasing weight loss.
DOV causes a decrease in circulating triglycerides.
The reason for weightloss is not going to be thermogenic or psychostimulant, or chronic decrease appetite. Read article for details.
See also [ edit ]
References [ edit ]
^ a b Mitchell, S. (2006-03-04). "SSRIs face next-generation replacement". United Press International.
^ a b Skolnick, P.; Krieter, P.; Tizzano, J.; Basile, A.; Popik, P.; Czobor, P.; Lippa, A. (2006). "Preclinical and Clinical Pharmacology of DOV 216,303, a "Triple" Reuptake Inhibitor". CNS Drug Reviews. 12 (2): 123–134. doi: 10.1111/j.1527-3458.2006.00123.x. PMID 16958986.